Description
ABT-301 is under investigation for the treatment of colorectal cancer and has shown promise in preclinical models by targeting a key pathway involved in tumor growth and progression; however, its clinical efficacy and safety profile are not yet established in human trials.
Mechanism of Action
ABT-301 is an investigational agent that targets the Wnt/ -catenin signaling pathway, which is often dysregulated in colorectal cancer; it inhibits ?-catenin stabilization and degradation.
Side Effects
Nausea; vomiting; fatigue; diarrhea; neutropenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07244705
Phase 1
Recruiting
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Australia, Taiwan